Notably, this aggressive variant of prostate cancer is frequently associated with low PSA production and therefore cannot be identified by PSA monitoring, which presents a great challenge for clinicians and an extremely poor prognosis for patients (3). This evidence concerns the gene KLK3 and Familial prostate cancer.